D-mannose in Multiple Sclerosis
Research type
Research Study
Full title
Single centre open-label feasibility study evaluating the use of D-mannose in Multiple sclerosis
IRAS ID
169422
Contact name
Jalesh Panicker
Contact email
Sponsor organisation
University College London
Duration of Study in the UK
0 years, 9 months, 30 days
Research summary
Multiple sclerosis (MS) is a common chronic immune-mediated, inflammatory, demyelinating, disorder of the central nervous system. Urinary tract infections (UTIs) are frequent in people with MS (pwMS) reporting lower urinary tract dysfunction. UTIs are known to precipitate acute relapse of MS. Furthermore recurrent UTIs significantly increase morbidity and mortality rates and have detrimental impact on quality of life. The options for preventing recurrent UTIs are limited. Long-term antibiotic prophylaxis is the most common strategy adopted, but they induce adverse reactions, costs and increased bacterial resistance to antibiotics. D-mannose is a relatively safe product, classed as a food supplement that prevents UTIs. Some studies have reported encouraging results in preventing UTIs in patients without neurological diseases. In this study we want to explore the feasibility of using D-mannose in pwMS reporting recurrent UTIs. This will be explored through assessing compliance to a 16-week course of D-mannose and quantifying the number of prescriptions for antibiotics during the 16 weeks course of D-mannose.
REC name
London - Bromley Research Ethics Committee
REC reference
14/LO/2262
Date of REC Opinion
22 Jan 2015
REC opinion
Favourable Opinion